ImmunityBio (IBRX) Competitors $2.74 -0.16 (-5.52%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.76 +0.02 (+0.88%) As of 08:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX vs. RGC, VRNA, BBIO, BPMC, ROIV, ELAN, RVMD, LEGN, GRFS, and NUVLShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Regencell Bioscience (RGC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. ImmunityBio vs. Its Competitors Regencell Bioscience Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols Nuvalent Regencell Bioscience (NASDAQ:RGC) and ImmunityBio (NASDAQ:IBRX) are both mid-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment. Do insiders and institutionals hold more shares of RGC or IBRX? 0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 76.8% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate RGC or IBRX? ImmunityBio has a consensus target price of $12.25, suggesting a potential upside of 347.08%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has better earnings and valuation, RGC or IBRX? Regencell Bioscience has higher earnings, but lower revenue than ImmunityBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegencell BioscienceN/AN/A-$4.30MN/AN/AImmunityBio$14.74M164.07-$413.56M-$0.58-4.72 Which has more risk and volatility, RGC or IBRX? Regencell Bioscience has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Is RGC or IBRX more profitable? Regencell Bioscience has a net margin of 0.00% compared to ImmunityBio's net margin of -1,310.30%. Company Net Margins Return on Equity Return on Assets Regencell BioscienceN/A N/A N/A ImmunityBio -1,310.30%N/A -121.88% Does the media refer more to RGC or IBRX? In the previous week, ImmunityBio had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for ImmunityBio and 3 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.24 beat ImmunityBio's score of 0.23 indicating that Regencell Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryImmunityBio beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks. Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.56B$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-4.7220.2228.5419.58Price / Sales164.07298.23430.1194.56Price / CashN/A43.1536.0257.93Price / Book-4.817.568.145.54Net Income-$413.56M-$55.11M$3.24B$257.73M7 Day Performance-1.79%3.81%0.17%-0.08%1 Month Performance-12.46%11.60%5.95%8.09%1 Year Performance-57.19%-2.11%26.22%13.02% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio2.1343 of 5 stars$2.74-5.5%$12.25+347.1%-56.9%$2.56B$14.74M-4.72590RGCRegencell Bioscience0.3405 of 5 stars$17.66-8.5%N/AN/A$9.11BN/A0.0010Positive NewsGap DownVRNAVerona Pharma PLC American Depositary Share2.2674 of 5 stars$104.80+20.6%$107.36+2.5%+387.3%$8.92B$42.28M-52.4030Analyst ForecastHigh Trading VolumeBBIOBridgeBio Pharma4.6361 of 5 stars$45.08+4.4%$58.93+30.7%+68.7%$8.53B$221.90M-12.72400Analyst ForecastAnalyst RevisionBPMCBlueprint Medicines1.0895 of 5 stars$128.41+0.0%$128.25-0.1%+8.2%$8.29B$508.82M-51.98640Positive NewsROIVRoivant Sciences2.8009 of 5 stars$11.20+3.1%$17.50+56.3%-1.2%$7.60B$29.05M-44.72860ELANElanco Animal Health1.6136 of 5 stars$14.72-0.2%$15.33+4.2%+9.4%$7.31B$4.44B19.889,000RVMDRevolution Medicines4.6031 of 5 stars$37.49+2.9%$68.00+81.4%-17.8%$6.95B$11.58M-9.33250Analyst ForecastGap UpLEGNLegend Biotech3.3629 of 5 stars$37.80+0.8%$72.60+92.1%-26.7%$6.93B$627.24M-63.902,609GRFSGrifols3.5155 of 5 stars$9.61+6.7%$10.30+7.2%+19.7%$6.61B$7.21B8.2223,822News CoverageGap UpNUVLNuvalent3.3016 of 5 stars$80.59+2.3%$119.60+48.4%+1.8%$5.79BN/A-18.3640 Related Companies and Tools Related Companies RGC Alternatives VRNA Alternatives BBIO Alternatives BPMC Alternatives ROIV Alternatives ELAN Alternatives RVMD Alternatives LEGN Alternatives GRFS Alternatives NUVL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IBRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBRX Stock Alerts